CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Sees Significant Decline in Short Interest

Key Points

• CSL Limited's short interest decreased by 83.3% in August, dropping from 7,800 shares to just 1,300 shares as of August 31st.
• The company's stock traded down 1.5% to $68.43 on Thursday, with a total trading volume of 257,954 shares.
• CSL Limited operates through segments such as CSL Behring and CSL Seqirus, focusing on biopharmaceuticals and vaccines across multiple countries.

CSL Limited Sponsored ADR (OTCMKTS:CSLLY - Get Free Report) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totaling 1,300 shares, a decrease of 83.3% from the August 15th total of 7,800 shares. Based on an average trading volume of 283,800 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company's shares are short sold. Currently, 0.0% of the company's shares are short sold. Based on an average trading volume of 283,800 shares, the days-to-cover ratio is presently 0.0 days.

CSL Price Performance

CSL stock traded down $0.57 during trading on Tuesday, reaching $67.04. The company had a trading volume of 89,159 shares, compared to its average volume of 179,416. CSL has a 12-month low of $64.68 and a 12-month high of $101.44. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12. The stock's 50 day moving average price is $78.63 and its two-hundred day moving average price is $78.67.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.